Evans Blue Conjugates for Albumin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for extending the half-life of therapeutic compounds, such as PEGylation and protein fusions, often compromise biological activity and have suboptimal biodistribution, particularly for diabetes treatment and cancer therapy, where albumin-based drug delivery systems face challenges in achieving efficient drug release and targeting.
Innovation Solution
Development of chemical conjugates of Evans Blue dye with therapeutic compounds, such as Exendin-4, which form stable complexes that bind to serum albumin, enhancing pharmacokinetics and biodistribution by prolonging circulation time and improving tissue targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If PEGylation is used to increase molecular size and reduce renal clearance, then circulation time is prolonged, but biological activity is compromised due to bulky PEG chain size
Solution Approach 1:
The patent changes the molecular weight parameter of the attached moiety from large PEG chains (typically 2-10 kDa) to smaller albumin molecules (66.5 kDa) that can be covalently attached without excessive bulk. This parameter change allows prolonging circulation time through increased molecular size while maintaining biological activity because the attachment is covalent and controlled, avoiding the masking effect of bulky PEG chains.
Solution Approach 2:
The patent uses albumin as an intermediary carrier molecule to attach therapeutic compounds to the Fc domain of IgG. This intermediary approach allows the therapeutic compound to be delivered with extended half-life through the FcRn pathway without requiring direct attachment of bulky PEG chains, thus maintaining biological activity while achieving prolonged circulation.
2Duration of action of stationary object
If lipid chains are conjugated to insulin or GLP-1 to increase circulation time, then binding to albumin occurs, but biodistribution is suboptimal with high accumulation in liver
Solution Approach 1:
The patent creates a composite structure combining the Fc domain of IgG with albumin-binding therapeutic compounds. This composite material leverages the FcRn recycling pathway for systemic distribution while albumin binding provides targeted delivery, achieving both prolonged circulation time and improved biodistribution away from liver accumulation.
Solution Approach 2:
The patent makes the Fc-albumin conjugate system multi-functional by combining the half-life extension capability of FcRn interaction with the targeting capability of albumin binding. This universal platform can deliver various therapeutic compounds (insulin, GLP-1, etc.) with both prolonged circulation and improved biodistribution to multiple tissue types beyond just the liver.
3Duration of action of stationary object
If protein fusion with albumin or IgG Fc domain is used to increase molecular size, then renal clearance is reduced, but the complexity of the fusion process increases
Solution Approach 1:
The patent segments the modification process into two independent steps: first, covalent attachment of the therapeutic compound to the Fc domain of IgG; second, binding of albumin to the therapeutic compound. This segmentation simplifies the overall process compared to creating a single complex fusion protein, as each step can be optimized and controlled independently.
Solution Approach 2:
The patent uses the therapeutic compound itself as an intermediary that bridges the Fc domain and albumin. Instead of directly fusing albumin to IgG (which would create a complex homogeneous fusion protein), the therapeutic compound mediates the interaction, allowing flexible conjugation with reduced process complexity and maintained drug functionality.
4Object-affected harmful factors
If covalent attachment of PEG to therapeutic compound is used to mask from immune system, then immunogenicity is reduced, but the hydrodynamic size increase reduces renal clearance
Solution Approach 1:
The patent replaces the need for long PEG chains (which provide both immunogenicity masking and half-life extension but with excessive bulk) with a more efficient combination: covalent attachment to Fc domain for immunogenicity masking, and albumin binding for half-life extension. This approach achieves the same protective effects with smaller overall molecular size increase, optimizing the balance between immune masking and circulation time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Evans Blue conjugates demonstrate prolonged half-life and improved biodistribution, maintaining therapeutic efficacy with enhanced stability and targeted delivery, as shown in preclinical studies, particularly for diabetes treatment and cancer therapy.
Implementation Method 1
chemical conjugates of Evans Blue dye with therapeutic compounds, such as Exendin-4, which form stable complexes that bind to serum albumin
Data Source
AI summary
The present invention is directed to a compound of Formula I or Formula II or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula I Formula II The compounds of Formula I may be covalently bonded to a therapeutic compound or fragment thereof to provide a compound of Formula II and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.